Comparative Pharmacology
Head-to-head clinical analysis: DECADRON W XYLOCAINE versus TRIACET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECADRON W XYLOCAINE versus TRIACET.
DECADRON W/ XYLOCAINE vs TRIACET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response. Lidocaine is a sodium channel blocker that stabilizes neuronal membranes, inhibiting nerve impulse initiation and conduction, producing local anesthesia.
Triacetin is a triester of glycerol and acetic acid. Its exact mechanism of action is not fully understood, but it exhibits antifungal activity by disrupting fungal cell membrane integrity and inhibiting fungal growth.
Not a standard pre-mixed combination; individual components dosed separately. Dexamethasone: 0.5-9 mg/day oral/IV divided every 6-12h. Lidocaine: 1-5 mg/kg IV bolus (max 300 mg), then 1-4 mg/min IV infusion; or local infiltration up to 4.5 mg/kg (max 300 mg) with epinephrine.
0.5-1 mg orally three times daily; maximum dose 4 mg/day.
None Documented
None Documented
Dexamethasone: 3-4 hours (short-acting steroid). Lidocaine: 1.5-2 hours (prolonged in heart failure/hepatic disease).
Terminal elimination half-life is approximately 3.5–4 hours in adults with normal renal function; may be prolonged (up to 6–8 hours) in patients with hepatic impairment.
Dexamethasone: Renal (~65% as metabolites, <10% unchanged); Biliary/Fecal (<35%). Lidocaine: Hepatic metabolism to MEGX; Renal (<10% unchanged).
Renal, unchanged drug: <1% of dose; metabolites: approximately 20% in urine, remainder in feces via biliary elimination.
Category C
Category C
Corticosteroid/Local Anesthetic Combination
Corticosteroid